Evotec Announces Chief Scientific Officer Transition
Why now
Thesis: Leadership transition adds execution risk to Evotec's science roadmap
Catalyst to watch: Successor appointment and pipeline updates
Main risk: Loss of scientific continuity during search
Why it matters
A CSO departure at a biotech can slow pipeline execution and signal internal strategy shifts, though a search is underway.
Details
Dr. Cord Dohrmann to step down as of September 30, 2026 Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-29 06:04 UTC